Movement Alert｜SPYRE THERAPEUTICS INC Rises 7.79% in Regular Trading, trading at 91.32 USD

Market Focus10-21

On October 21, SPYRE THERAPEUTICS INC rose 7.79% in Regular Trading, trading at 91.32 USD/share, with Turnover of 51.41 million USD.

Within the Biotechnology sector where SPYRE THERAPEUTICS INC belongs, peer stocks also moved higher, with Moderna, Inc. up 3.2%, AbbVie up 2.29%, Gilead Sciences up 1.53%, Amgen up 2.1%, and Argenx SE up 5.75%.

Recent company developments show SPYRE THERAPEUTICS INC previously reported positive Phase 2 data for SPY003 in ulcerative colitis, including a 20% clinical-remission rate and 30% endoscopic-improvement rate at week 12, while earlier filings also indicated cash, cash equivalents, and marketable securities of 741.5 million USD expected to fund operations into the second half of 2029. However, no same-day specific news catalyst was identified for this move.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment